Politics / Law

Acceptance for evaluating authority in consumer drug information

16.11.2009

Brussels/Strasbourg – The pharmaceutical industry has agreed to accept a review of direct-to-consumer information on prescription medicines prior to its publication on the Internet or in newspapers. According to Euractiv, EFPIA chief Arthur Higgins confirmed in November that a majority of the members in the EU pharma association have agreed to the establishment of an independent authority with the power to decide whether data on how the drug works, its interactions and side-effects are purely factual. Experts say this should help pacify critics of the EU’s pharmaceutical package, which is to allow the industry to communicate directly to consumers. Critics have argued that allowing companies to provide information on their own products would open the door to direct advertising for prescription medicines. At a meeting with EU parliamentarians organised by conservative French MEP Françoise Grossetête, Higgins criticised EU health ministers for having apparently shelved a plan to provide high-quality information on diseases and treatments to consumers. “Patients need to be equipped to make informed choices,” he said, and has lobbied MEPs and patient organisations to prevent the proposal from being diluted or dropped.
Direct-to-consumer advertising (DTCA) is currently only permitted in the US and New Zealand. Pharma companies are primarily interested in so-called product claim advertisements, which link the brand names of certain pharmaceuticals with claims about indications and efficacy. Most industry analysts agree that the intent behind investing in such advertisements is unquestionably to generate a financial return. According to IMS Management Consulting, which analysed sales increases in 49 advertised US brands, the return on investment “is nearly unprecedented in terms of the positive sales response generated.”
Having proven an effective means of marketing that complements campaigns targeting health professionals, annual investments in DTCA in the US climbed from US$35m in 1996 to US$4.25bn in 2005. According to estimates, DTCA in the US already makes up around 15% of total expenditures on pharma promotions.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/acceptance-for-evaluating-authority-in-consumer-drug-information.html

Events

All Events

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • EPIGENOMICS3.78 EUR11.83%
  • MOLOGEN7.75 EUR6.02%

FLOP

  • SANTHERA92.70 CHF-7.39%
  • MEDIGENE4.40 EUR-2.87%
  • ADDEX3.82 CHF-2.80%

TOP

  • SANTHERA92.70 CHF54.8%
  • EPIGENOMICS3.78 EUR18.1%
  • BB BIOTECH143.70 EUR11.1%

FLOP

  • WILEX2.40 EUR-11.1%
  • BIOFRONTERA2.40 EUR-10.4%
  • VITA 343.77 EUR-9.4%

TOP

  • SANTHERA92.70 CHF3965.8%
  • CO.DON2.45 EUR184.9%
  • PAION2.38 EUR158.7%

FLOP

  • CYTOS0.26 CHF-93.7%
  • MEDIGENE4.40 EUR-70.1%
  • MERCK KGAA66.43 EUR-42.9%

No liability assumed, Date: 01.09.2014


Current issue

All issues

Product of the week

Products